Skip to main content
Clinical Trials/NCT04385082
NCT04385082
Recruiting
Phase 1

Sex-dependent Effects of Cannabis: Assessing Analgesic, Abuse-related and Pharmacokinetic Differences Between Men and Women

University of California, Los Angeles1 site in 1 country160 target enrollmentJuly 8, 2021

Overview

Phase
Phase 1
Intervention
Placebo Cannabis
Conditions
Pain
Sponsor
University of California, Los Angeles
Enrollment
160
Locations
1
Primary Endpoint
Pharmacokinetics of THC and metabolites
Status
Recruiting
Last Updated
last month

Overview

Brief Summary

The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-related effects between men and women

Detailed Description

The proposed study will compare smoked cannabis's dose-dependent, analgesic and abuse-related effects between men and women and variables that underlie these sex-dependent differences, including pharmacokinetics of THC.

Registry
clinicaltrials.gov
Start Date
July 8, 2021
End Date
July 1, 2027
Last Updated
last month
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ziva D. Cooper, PhD

Associate Professor

University of California, Los Angeles

Eligibility Criteria

Inclusion Criteria

  • Male or non-pregnant female aged 21-55 years
  • Report use of cannabis an average of 1-7 days per week
  • Not currently seeking treatment for their cannabis use
  • Urine test positive for recent cannabis use for heavy users
  • No reported adverse effects with cannabis smoking in light users
  • Have a Body Mass Index from 18.5 - 34kg/m
  • Able to perform all study procedures
  • FEMALES: Currently practicing a non-hormonal effective form of birth control
  • FEMALES: Must be regularly cycling

Exclusion Criteria

  • Meeting DSM-V criteria for any substance use disorder other than nicotine, caffeine, or cannabis use disorder
  • Report using other illicit drugs in the prior 4 weeks
  • History or current evidence of severe psychiatric illness or medical condition judged by the study physician and PI to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
  • Current use of medical cannabis, prescription analgesics, or any medications that may affect study outcomes
  • Current pain
  • Insensitivity to the cold water stimulus of the Cold Pressor Test
  • FEMALES: using a hormonal contraceptive

Arms & Interventions

Placebo

Smoked Cannabis (\~0% THC)

Intervention: Placebo Cannabis

Low strength cannabis

Smoked Cannabis (\~4% THC)

Intervention: Active Cannabis

Higher strength cannabis

Smoked Cannabis (\~10% THC)

Intervention: Active Cannabis

Outcomes

Primary Outcomes

Pharmacokinetics of THC and metabolites

Time Frame: 5 hours

Plasma levels of THC, 11-OH-THC, and THCCOOH

Subject-rated drug effects

Time Frame: 5 hours

Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm).

Analgesia as measured using the Cold Pressor Test

Time Frame: 5 hours

Peak and average pain threshold and tolerance assessed using the Cold Pressor Test

Secondary Outcomes

  • Drug reinforcement using the cannabis self-administration task(5 hours)

Study Sites (1)

Loading locations...

Similar Trials